Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Add-on tacrolimus provides short-term survival gains in PM/DM-interstitial pneumonia

21 Oct 2019

Initial treatment with tacrolimus and glucocorticoids (GCs) appears to improve short-term mortality in polymyositis (PM)/dermatomyositis (DM)-interstitial pneumonia patients, according to a recent study.

A total of 25 patients (mean age, 55.4 years; 76 percent female) received initial combination treatment with tacrolimus (0.075 mg/kg/day, adjusted for the target whole-blood trough levels between 5 and 10 ng/ml) and glucocorticoids (0.6–1.0 mg/kg/day of prednisolone followed by a slow taper) for 52 weeks.

The primary outcome of overall survival at 52 weeks was 88.0 percent (95 percent CI, 67.3–96.0 percent). Progression-free survival rate was 76.4 percent (51.8–89.5 percent).

Whole-blood tacrolimus trough levels were preserved within the targeted range of 5 and 10 ng/ml throughout the study period (average, 6.6 ng/ml), with an average daily dose of 3.81 mg/day (0.072 mg/kg/day).

The safety profile of the combination treatment was consistent with the known adverse event (AE) profile of tacrolimus and high-dose GCs individually. A total of 11 patients (44 percent) developed serious adverse events, which included four opportunistic infections.

In total, there were 475 AEs recorded, of which 357 (75.2 percent) were deemed possibly, probably or definitely associated with tacrolimus or GCs by treating physicians.

The current prospective clinical investigation was the first to be conducted according to the Good Clinical Practice Guideline of the International Conference on Harmonization for the treatment of PM/DM-interstitial pneumonia.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.